KennethALichtensteinMD
Infectious Disease • Palm Springs, CAProfessor, Medicine, University of Colorado School of Medicine
Dr. Lichtenstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4791 E Palm Canyon Dr Ste 200
Palm Springs, CA 92264Phone+1 760-834-7950
Education & Training
University of ColoradoFellowship, Infectious Disease, 1976 - 1978- University of ColoradoResidency, Internal Medicine, 1973 - 1976
- University of Colorado School of Medicine Anschutz Medical CampusClass of 1973
Certifications & Licensure
CA State Medical License 2015 - 2023
CO State Medical License 1974 - 2019
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen Start of enrollment: 2008 Jul 01
Publications & Presentations
PubMed
- 6 citationsExcess heart age in adult outpatients in routine HIV careAngela M. Thompson-Paul, Frank J. Palella, Nabil Rayeed, Matthew D. Ritchey, Kenneth A. Lichtenstein
AIDS. 2019-10-01 - 94 citationsContributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV...Keri N. Althoff, Kelly A. Gebo, Richard D. Moore, Cynthia M. Boyd, Amy C. Justice
The Lancet. HIV. 2019-02-01 - 44 citationsBrief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal ImpairmentFrank A. Post, Pablo Tebas, Amanda Clarke, Laurent Cotte, William R. Short
Journal of Acquired Immune Deficiency Syndromes. 2017-02-01
Press Mentions
Coachella Valley Hospitals Offer Monoclonal Antibodies for High-Risk COVID-19 PatientsFebruary 3rd, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
